-
公开(公告)号:US08618303B2
公开(公告)日:2013-12-31
申请号:US13342122
申请日:2012-01-02
申请人: Henner Knust , Matthias Nettekoven , Hasane Ratni , Walter Vifian
发明人: Henner Knust , Matthias Nettekoven , Hasane Ratni , Walter Vifian
IPC分类号: C07D401/06 , A61K31/445
CPC分类号: C07D401/06 , C07D401/14 , C07D403/06 , C07D407/06 , C07D413/10
摘要: The invention provides compounds of formula wherein R1, R2, R3, R4, R5, and R6 are as defined herein or a pharmaceutically suitable acid addition salt thereof. The present compounds are high potential NK-3 receptor antagonists useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译: 本发明提供下式的化合物,其中R 1,R 2,R 3,R 4,R 5和R 6如本文所定义,或其药学上合适的酸加成盐。 本发明化合物是可用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。
-
公开(公告)号:US08324248B2
公开(公告)日:2012-12-04
申请号:US12692680
申请日:2010-01-25
申请人: Henner Knust , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
发明人: Henner Knust , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
IPC分类号: A61K31/445 , C07D401/14
CPC分类号: C07D413/14 , C07D401/12 , C07D401/14
摘要: The present invention relates to a compounds of formula I wherein A, Ar1, Ar2, R1, R2, R3, R4, R5, R6, m, n, o, p, s, t, and u are as defined herein or to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译: 本发明涉及式I化合物,其中A,Ar1,Ar2,R1,R2,R3,R4,R5,R6,m,n,o,p,s,t和u如本文所定义, 药物活性盐,外消旋混合物,对映体,旋光异构体或其互变异构形式。 本发明化合物是用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。
-
公开(公告)号:US20120178761A1
公开(公告)日:2012-07-12
申请号:US13342122
申请日:2012-01-02
申请人: Henner Knust , Matthias Nettekoven , Hasane Ratni , Walter Vifian
发明人: Henner Knust , Matthias Nettekoven , Hasane Ratni , Walter Vifian
IPC分类号: A61K31/454 , C07D207/14 , A61P25/18 , C07D403/06 , A61K31/501 , C07D401/06 , A61K31/40
CPC分类号: C07D401/06 , C07D401/14 , C07D403/06 , C07D407/06 , C07D413/10
摘要: The invention provides compounds of formula wherein R1, R2, R3, R4, R5, and R6 are as defined herein or a pharmaceutically suitable acid addition salt thereof. The present compounds are high potential NK-3 receptor antagonists useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译: 本发明提供下式的化合物,其中R 1,R 2,R 3,R 4,R 5和R 6如本文所定义,或其药学上合适的酸加成盐。 本发明化合物是可用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。
-
公开(公告)号:US08324250B2
公开(公告)日:2012-12-04
申请号:US12721587
申请日:2010-03-11
申请人: Henner Knust , Anja Limberg , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
发明人: Henner Knust , Anja Limberg , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
IPC分类号: A61K31/445 , C07D413/02
CPC分类号: C07D401/10 , A61K31/4409 , A61K31/4465 , C07D211/32 , C07D401/14 , C07D409/14 , C07D413/10 , C07D417/10 , C07D417/14
摘要: The present application relates to compounds of formula wherein the definitions are as described herein. The present compounds are high potential NK-3 receptor antagonists that are useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译: 本申请涉及下式的化合物,其中定义如本文所述。 本发明化合物是可用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。
-
公开(公告)号:US08318749B2
公开(公告)日:2012-11-27
申请号:US12614474
申请日:2009-11-09
申请人: Henner Knust , Anja Limberg , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
发明人: Henner Knust , Anja Limberg , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
IPC分类号: A61K31/517 , C07D239/70 , C07D401/04
CPC分类号: C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14
摘要: The present invention relates to a compounds of formula I wherein R1, R2, R3, R4, R5, and n are as defined herein and to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译: 本发明涉及式Ⅰ化合物,其中R 1,R 2,R 3,R 4,R 5和n如本文所定义,并且涉及药物活性盐,外消旋混合物,对映异构体,旋光异构体或其互变异构形式。 本发明化合物是用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。
-
公开(公告)号:US20100125078A1
公开(公告)日:2010-05-20
申请号:US12614474
申请日:2009-11-09
申请人: Henner Knust , Anja Limberg , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
发明人: Henner Knust , Anja Limberg , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
IPC分类号: A61K31/498 , C07D401/14 , C07D403/04 , A61K31/517 , A61P25/18
CPC分类号: C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14
摘要: The present invention relates to a compounds of formula I wherein R1, R2, R3, R4, R5, and n are as defined herein and to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译: 本发明涉及式Ⅰ化合物,其中R 1,R 2,R 3,R 4,R 5和n如本文所定义,并且涉及药物活性盐,外消旋混合物,对映异构体,旋光异构体或其互变异构形式。 本发明化合物是用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。
-
公开(公告)号:US20100256126A1
公开(公告)日:2010-10-07
申请号:US12721587
申请日:2010-03-11
申请人: Henner Knust , Anja Limberg , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
发明人: Henner Knust , Anja Limberg , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
IPC分类号: A61K31/451 , C07D417/10 , C07D211/62 , C07D401/10 , C07D413/10 , C07D413/14 , C07D417/14 , A61K31/541 , A61K31/4545 , A61K31/5377 , A61K31/506 , A61K31/497 , A61K31/454
CPC分类号: C07D401/10 , A61K31/4409 , A61K31/4465 , C07D211/32 , C07D401/14 , C07D409/14 , C07D413/10 , C07D417/10 , C07D417/14
摘要: The present application relates to compounds of formula wherein the definitions are as described herein. The present compounds are high potential NK-3 receptor antagonists that are useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译: 本申请涉及下式的化合物,其中定义如本文所述。 本发明化合物是可用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。
-
公开(公告)号:US20090076081A1
公开(公告)日:2009-03-19
申请号:US12207596
申请日:2008-09-10
申请人: Henner Knust , Matthias Nettekoven , Hasane Ratni , Walter Vifian , Xihan Wu
发明人: Henner Knust , Matthias Nettekoven , Hasane Ratni , Walter Vifian , Xihan Wu
IPC分类号: A61K31/445 , C07D211/22 , A61K31/4523 , A61P25/24 , A61P25/16 , C07D401/04
CPC分类号: C07D211/58 , C07D401/04
摘要: The invention relates to a compound of formula wherein Ar1, Ar2, R1, R2, R3, R4, R5, and R5′ or to a pharmaceutically active salt thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译: 本发明涉及下式化合物其中Ar1,Ar2,R1,R2,R3,R4,R5和R5'或其药物活性盐。 这些化合物是用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。
-
公开(公告)号:US20110152233A1
公开(公告)日:2011-06-23
申请号:US12964769
申请日:2010-12-10
申请人: Henner Knust , Andreas Koblet , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
发明人: Henner Knust , Andreas Koblet , Matthias Nettekoven , Hasane Ratni , Claus Riemer , Walter Vifian
IPC分类号: A61K31/397 , A61K31/501 , A61K31/4965 , A61K31/506 , A61K31/4545 , C07D405/14 , C07D401/14 , C07D401/08
CPC分类号: C07D401/14 , C07D207/14 , C07D401/06 , C07D405/14
摘要: The present application relates to compounds of formula wherein R1, R2, R3, R4, and n are defined herein or to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译: 本申请涉及下式的化合物,其中R 1,R 2,R 3,R 4和n在本文中定义或其药物活性盐。 本发明化合物是用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。
-
公开(公告)号:US20110021565A1
公开(公告)日:2011-01-27
申请号:US12896987
申请日:2010-10-04
申请人: Henner Knust , Matthias Nettekoven , Hasane Ratni , Walter Vifian , Xihan Wu
发明人: Henner Knust , Matthias Nettekoven , Hasane Ratni , Walter Vifian , Xihan Wu
IPC分类号: A61K31/4545 , C07D211/58 , C07D401/12 , C07D403/04 , C07D403/14 , A61K31/4468 , A61K31/454 , A61P25/18 , A61P25/16 , A61P25/22 , A61P25/00 , A61P25/24
CPC分类号: C07D211/58 , C07D401/04
摘要: The invention relates to a compound of formula wherein Ar1, Ar2, R1, R2, R3, R4, R5, and R5′ or to a pharmaceutically active salt thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译: 本发明涉及下式化合物其中Ar1,Ar2,R1,R2,R3,R4,R5和R5'或其药物活性盐。 这些化合物是用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。
-
-
-
-
-
-
-
-
-